Literature DB >> 20605976

Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Weidang Li1, Ashlesh K Murthy, M Neal Guentzel, James P Chambers, Thomas G Forsthuber, J Seshu, Guangming Zhong, Bernard P Arulanandam.   

Abstract

We have previously demonstrated the efficacy of recombinant chlamydial protease-like activity factor (rCPAF; a secreted chlamydial protein) in inducing antigen-specific CD4+ T cell/gamma interferon (IFN-gamma)-mediated but not antibody-mediated chlamydial clearance and reduction of upper genital tract (UGT) pathological sequelae. Since chlamydial integral antigens may induce neutralizing antibody protection, we further evaluated induction of protective immunity using a combination of rCPAF and UV-inactivated chlamydial elementary bodies (UV-EB) against vaginal chlamydial challenge in comparison to immunization with the individual components or live EB. The rCPAF-UV-EB immunization induced a significantly enhanced anti-UV-EB cellular and antibody response and a reduced anti-CPAF cellular and antibody response, compared to immunization with the respective individual components. Moreover, vaccination with UV-EB and rCPAF-UV-EB induced serum antibodies that neutralized chlamydial infectivity. The rCPAF-UV-EB immunization resulted in a significant reduction of vaginal chlamydial shedding and induced earlier bacterial clearance than vaccination of mice with the individual components. Importantly, the UGT sequelae were significantly reduced in mice immunized with rCPAF or rCPAF-UV-EB, but not in those immunized with UV-EB alone, and approached the levels of protection induced by live EB. These results collectively suggest that a combination of neutralizing antibodies induced by integral chlamydial antigens and cell-mediated responses induced by secreted proteins such as CPAF induces optimal protective immunity against genital chlamydial infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605976      PMCID: PMC2937460          DOI: 10.1128/IAI.00346-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

2.  The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells.

Authors:  Cathi Murphey; Ashlesh K Murthy; Patricia A Meier; M Neal Guentzel; Guangming Zhong; Bernard P Arulanandam
Journal:  Cell Immunol       Date:  2006-11-20       Impact factor: 4.868

3.  A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection.

Authors:  Sandra G Morrison; Richard P Morrison
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

4.  Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele.

Authors:  Ashlesh K Murthy; Yu Cong; Cathi Murphey; M Neal Guentzel; Thomas G Forsthuber; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-10-02       Impact factor: 3.441

5.  Monitoring the T cell response to genital tract infection.

Authors:  Nadia R Roan; Todd M Gierahn; Darren E Higgins; Michael N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

6.  Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species.

Authors:  Feng Dong; Youmin Zhong; Bernard Arulanandam; Guangming Zhong
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

Review 7.  Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine.

Authors:  Robert C Brunham; José Rey-Ladino
Journal:  Nat Rev Immunol       Date:  2005-02       Impact factor: 53.106

8.  Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; J Seshu; Thomas G Forsthuber; Guangming Zhong; Bernard P Arulanandam
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

9.  Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach.

Authors:  Weidang Li; M Neal Guentzel; J Seshu; Guangming Zhong; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2007-10-17

10.  Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.

Authors:  Yu Cong; Madhulika Jupelli; M Neal Guentzel; Guangming Zhong; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Vaccine       Date:  2007-02-23       Impact factor: 3.641

View more
  11 in total

Review 1.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator.

Authors:  Chunxue Lu; Bo Peng; Zhihong Li; Lei Lei; Zhongyu Li; Lili Chen; Qingzhi He; Guangming Zhong; Yimou Wu
Journal:  Microbes Infect       Date:  2013-02-14       Impact factor: 2.700

3.  Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.

Authors:  Weidang Li; Pareesha Gudipaty; Chuxi Li; Kyle K Henderson; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Immunol Cell Biol       Date:  2018-08-23       Impact factor: 5.126

4.  Plac8-dependent and inducible NO synthase-dependent mechanisms clear Chlamydia muridarum infections from the genital tract.

Authors:  Raymond M Johnson; Micah S Kerr; James E Slaven
Journal:  J Immunol       Date:  2012-01-11       Impact factor: 5.422

Review 5.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

6.  A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.

Authors:  Weidang Li; Ashlesh K Murthy; Gopala Krishna Lanka; Senthilnath L Chetty; Jieh-Juen Yu; James P Chambers; Guangming Zhong; Thomas G Forsthuber; M Neal Guentzel; Bernard P Arulanandam
Journal:  Vaccine       Date:  2013-10-01       Impact factor: 3.641

7.  Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs.

Authors:  Shradha Wali; Rishein Gupta; Jieh-Juen Yu; Gopala Krishna Koundinya Lanka; James P Chambers; M Neal Guentzel; Guangming Zhong; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Immunol Cell Biol       Date:  2016-12-19       Impact factor: 5.126

8.  Immunization with dendritic cells pulsed ex vivo with recombinant chlamydial protease-like activity factor induces protective immunity against genital chlamydiamuridarum challenge.

Authors:  Weidang Li; Ashlesh K Murthy; B K R Chaganty; M Neal Guentzel; J Seshu; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Front Immunol       Date:  2011-12-08       Impact factor: 7.561

9.  A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs.

Authors:  Sarah Bøje; Anja Weinreich Olsen; Karin Erneholm; Jørgen Steen Agerholm; Gregers Jungersen; Peter Andersen; Frank Follmann
Journal:  Immunol Cell Biol       Date:  2015-08-13       Impact factor: 5.126

10.  Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract.

Authors:  Jeanette Erbo Wern; Maria Rathmann Sorensen; Anja Weinreich Olsen; Peter Andersen; Frank Follmann
Journal:  Front Immunol       Date:  2017-05-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.